Complementary and alternative medicine for autism spectrum disorders: Rationale, safety and efficacy

Journal of Paediatrics and Child Health

Volumn 49, Issue 9, 2013, Pages

  Whitehouse, Andrew J O ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

alternative medicine; autism; autism spectrum disorder; complementary medicine; efficacy

Indexed keywords

CASEIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; MAGNESIUM; MELATONIN; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXINE; SECRETIN;

ADVERSE OUTCOME; ALTERNATIVE MEDICINE; AUTISM; BLOOD BRAIN BARRIER; CASEIN FREE DIET; CHILD BEHAVIOR; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DIET THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EPISTAXIS; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUTEN FREE DIET; HUMAN; HYPERACTIVITY; HYPERBARIC OXYGEN; IMMUNOTHERAPY; INSOMNIA; LOW CARBOHYDRATE DIET; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SLEEP TIME; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

ALTERNATIVE MEDICINE; AUTISM; AUTISM SPECTRUM DISORDER; COMPLEMENTARY MEDICINE; EFFICACY;

CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMPLEMENTARY THERAPIES; DIET, GLUTEN-FREE; FATTY ACIDS, OMEGA-3; GASTROINTESTINAL AGENTS; HUMANS; HYPERBARIC OXYGENATION; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MELATONIN; SECRETIN; TREATMENT OUTCOME; VITAMINS;

EID: 84883806432     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12242     Document Type: Review

References (50)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington: American Psychiatric Association, 2000.
2. Williams K, Glasson EJ, Wray J, et al. Incidence of autism spectrum disorders in children in two Australian states. Med. J. Aust. 2005; 182: 108-111.
3. Centers for Disease Control and Prevention. Mental health in the United States: parental report of diagnosed autism in children aged 4-17 years-United States, 2003-2004. MMWR Morbid. Mortal. Wkly. Rep. 2006; 55: 481-486.
4. Eldevik S, Hastings RP, Hughes JC, et al. Meta-analysis of early intensive behavioral intervention for children with autism. J. Clin. Child Adolesc. Psychol. 2009; 38: 439-450.
5. McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011; 127: e1312-1321.
6. Akins RS, Angkustsiri K, Hansen RL,. Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families. Neurotherapeutics 2010; 7: 307-319.
7. Hanson E, Kalish L, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J. Autism Dev. Disord. 2007; 37: 628-636.
8. Harrington JW, Rosen L, Garnecho A, Patrick PA,. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J. Dev. Behav. Pediatr. 2006; 27 (2 Suppl.): S156-161.
9. Wong HH, Smith RG,. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J. Autism Dev. Disord. 2006; 36: 901-909.
10. MacLennan AH, Myers SP, Taylor AW,. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med. J. Aust. 2006; 184: 27-31.
11. Elder JH,. The gluten-free, casein-free diet in autism: an overview with clinical implications. Nutr. Clin. Pract. 2008; 23: 583-588.
12. Knivsberg AM, Reichelt KL, Høien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr. Neurosci. 2002; 5: 251-261.
13. Elder J, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L,. The gluten-free, casein-free diet: results of a preliminary double blind clinical trial. J. Autism Dev. Disord. 2006; 36: 413-420.
14. Millward C, Ferriter M, Calver S, et al. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst. Rev. 2008; 2: CD003498.
15. Johnson C, Handen B, Zimmer M, Sacco K, Turner K,. Effects of gluten free/casein free diet in young children with autism: a pilot study. J. Dev. Phys. Disabil. 2011; 23: 213-225.
16. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT,. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Phys. 1998; 9: 9-15.
17. Williams KW, Wray JJ, Wheeler DM,. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst. Rev. 2009; 2: CD003495.
18. Dunn-Geier J, Ho H, Auersperg E, et al. Effect of secretin on children with autism: a randomised controlled trial. Dev. Med. Child Neurol. 2000; 42: 796-802.
19. Kern J, Miller V, Evans P, Trivedi M,. Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J. Autism Dev. Disord. 2002; 32: 153-160.
20. Roberts W, Weaver L, Brian J, et al. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics 2001; 107: e71.
21. Cajochen C, Kräuchi K, Wirz-Justice A,. Role of melatonin in the regulation of human circadian rhythms and sleep. J. Neuroendocrinol. 2003; 15: 432-437.
22. Richdale AL, Schreck KA,. Sleep problems in autism spectrum disorders: prevalence, nature, and possible biopsychosocial aetiologies. Sleep Med. Rev. 2009; 13: 403-411.
23. Jan JE, Freeman RD, Fast DK,. Melatonin treatment of sleep-wake cycle disorders in children and adolescents. Dev. Med. Child Neurol. 1999; 41: 491-500.
24. Garstang J, Wallis M,. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006; 32: 585-589.
25. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J. Pineal Res. 2008; 44: 57-64.
26. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J. Clin. Sleep Med. 2009; 5: 145-150.
27. Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behavior management strategies: a randomized controlled crossover trial. J. Autism Dev. Disord. 2010; 41: 175-184.
28. McArthur AJ, Budden SS,. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev. Med. Child Neurol. 1998; 40: 186-192.
29. Rossignol DA, Frye RE,. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev. Med. Child Neurol. 2011; 53: 783-792.
30. Andersen IM, Kaczmarska J, McGrew SG, et al. Melatonin for insomnia in children with autism spectrum disorders. J. Child Neurol. 2008; 23: 482-485.
31. Shamseer L, Vohra S,. Complementary, holistic, and integrative medicine: melatonin. Pediatr. Rev. 2009; 30: 223-228.
32. Rossignol DA,. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med. Hypotheses 2007; 68: 1208-1227.
33. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009; 9: 21.
34. Granpeesheh D, Tarbox J, Dixon DR, Wilke AE, Allen MS, Bradstreet JJ,. Randomized trial of hyperbaric oxygen therapy for children with autism. Res. Autism Spectr. Disord. 2010; 4: 268-275.
35. Bennett M, Hart B,. UHMS position paper: the treatment of autism spectrum disorder with hyperbaric oxygen therapy [Internet]. Aug. 13, 2012. Available from: http://membership.uhms.org/resource/%20resmgr/position-papers/autism- position-paper.pdf [accessed 10 May 2013].
36. Tibbles PM, Edelsberg JS,. Hyperbaric-oxygen therapy. N. Engl. J. Med. 1996; 334: 1642-1648.
37. Bösnich E,. 1968 Experiences with pyrithioxin in brain damaged children with autistic syndrome. Prax. Kinderpsychol. Kinderpsychiatr. 1968; 17: 308-310.
38. Nickl-Jockschat T, Michel TM,. The role of neurotrophic factors in autism. Mol. Psychiatry 2011; 16: 478-490.
39. Nye C, Brice A,. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst. Rev. 2009; 4: CD003497.
40. Findling RL, Maxwel K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J. Autism Dev. Disord. 1997; 27: 467-478.
41. Tolbert L, Haigler T, Waits MM, Dennis T,. Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J. Autism Dev. Disord. 1993; 23: 193-199.
42. Kuriyama S, Kamiyama M, Watanabe M, et al. Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Dev. Med. Child Neurol. 2002; 44: 283-286.
43. Schaumberg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N. Engl. J. Med. 1983; 309: 445-448.
44. Salem N, Litman B, Kim HY, Gawrisch K,. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-959.
45. Bell JG, MacKinlay EE, Dick JR, et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot. Essent. Fatty Acids 2004; 71: 201-204.
46. Bent S, Bertoglio K, Hendren RL,. Omega-3 fatty acids for autistic spectrum disorder: a systematic review. J. Autism Dev. Disord. 2009; 39: 1145-1154.
47. Amminger GP, Berger GE, Schäfer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry 2007; 61: 551-553.
48. Gupta S,. Immunological treatments for autism. J. Autism Dev. Disord. 2000; 30: 475-479.
49. Niederhofer H, Staffen W, Mair A,. Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder. Neuropsychopharmacology 2003; 28: 1014-1015.
50. Handen B, Melmed R, Hansen R, et al. A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J. Autism Dev. Disord. 2009; 39: 796-805